Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know
Whitehawk shares surged as much as 67% on Oct. 16 after announcing a multi-year collaboration with Tempus to use AI and real-world patient data in cancer drug development. The stock traded above $3.00 early Wednesday, up from a $2.10 close the previous day. Whitehawk plans to file INDs for its lead antibody-drug conjugates by late 2025. The company reported $177.2 million in cash at the end of June.
